{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-036825","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.089558+00:00","generated_at":"2026-05-29T06:35:37.125406+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monopar doses first patient with uPAR-targeted radiopharmaceutical MNPR-101-Lu","bullets":["First patient dosed under US compassionate use protocol for metastatic pancreatic cancer.","MNPR-101-Lu targets uPAR; infusion well-tolerated with no serious adverse reactions.","Patient's tumor showed uPAR expression via prior MNPR-101-Zr PET/CT imaging.","Two Phase 1 studies ongoing in Australia for MNPR-101-Zr (imaging) and MNPR-101-Lu (treatment).","Company believes this is the world's first dosing of a uPAR-targeted therapeutic radiopharmaceutical."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-036825","json":"https://secwatch.observer/filing/0001437749-24-036825.json","markdown":"https://secwatch.observer/filing/0001437749-24-036825.md","text":"https://secwatch.observer/filing/0001437749-24-036825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924036825/0001437749-24-036825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924036825/mnpr20241205_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T06:35:37.125406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}